Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial

OBJECTIVE: To evaluate whether favipiravir reduces the time to viral clearance as documented by negative RT-PCR results for severe acute respiratory syndrome coronavirus 2 in mild cases of coronavirus disease 2019 (COVID-19) compared to placebo. METHODS: In this randomized, double-blinded, multicent...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosaeed, Mohammad, Alharbi, Ahmad, Mahmoud, Ebrahim, Alrehily, Sanaa, Bahlaq, Mohannad, Gaifer, Zied, Alturkistani, Hanan, Alhagan, Khaled, Alshahrani, Saad, Tolbah, Ali, Musattat, Abrar, Alanazi, Maha, Jaha, Raniah, Sultana, Khizra, Alqahtani, Hajar, Al Aamer, Kholoud, Jaser, Saud, Alsaedy, Abdulrahman, Ahmad, Ayoub, Abalkhail, Mohammed, AlJohani, Sameera, Al Jeraisy, Majed, Almaziad, Sultan, Albaalharith, Nahlah, Alabdulkareem, Khaled, Alshowair, Abdulmajeed, Alharbi, Naif Khalaf, Alrabiah, Fahad, Alshamrani, Majid, Aldibasi, Omar, Alaskar, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747778/
https://www.ncbi.nlm.nih.gov/pubmed/35026375
http://dx.doi.org/10.1016/j.cmi.2021.12.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747778/
https://www.ncbi.nlm.nih.gov/pubmed/35026375
http://dx.doi.org/10.1016/j.cmi.2021.12.026

Ejemplares similares